Ken Griffin Maxcyte, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.68 - $5.06 $2,576 - $3,541	-700 Reduced 25.93%	2,000 $7,000
Q2 2024 Aug 14, 2024	BUY	$3.63 - $5.0 $2,178 - $3,000	600 Added 28.57%	2,700 $10,000
Q1 2024 May 15, 2024	SELL	$3.94 - $5.38 $2,364 - $3,228	-600 Reduced 22.22%	2,100 $8,000
Q4 2023 Feb 14, 2024	SELL	$2.6 - $5.24 $17,160 - $34,584	-6,600 Reduced 70.97%	2,700 $12,000
Q3 2023 Nov 14, 2023	BUY	$3.02 - $5.1 $16,006 - $27,029	5,300 Added 132.5%	9,300 $29,000
Q2 2023 Aug 14, 2023	BUY	$3.69 - $5.35 $5,166 - $7,489	1,400 Added 53.85%	4,000 $18,000
Q1 2023 May 15, 2023	BUY	$4.03 - $5.89 $7,657 - $11,191	1,900 Added 271.43%	2,600 $12,000
Q4 2022 Feb 14, 2023	BUY	$4.92 - $7.4 $3,444 - $5,180	700 New	700 $3,000

124

65.6M

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $348M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.